Third Harmonic Bio, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the development of medicine for the treatment of allergic and inflammatory diseases. Third Harmonic Bio serves customers in the United States.

Current Report (Form 8-K | Period ending 2024-05-15)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Third Harmonic Bio (THRD US)

Current Report (Form 8-K | Period ending 2024-05-15)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Annual Report to Security Holders (Form ARS | Period ending 2023-12-31)

Current Report (Form 8-K | Period ending 2024-03-27)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)